Welcome to our dedicated page for Mdxhealth Sa news (Ticker: MDXH), a resource for investors and traders seeking the latest updates and insights on Mdxhealth Sa stock.
MDxHealth SA reports developments in urology-focused precision diagnostics, including molecular tests used in the diagnosis and prognosis of prostate cancer and other urologic diseases. The company’s test menu is based on genomic, epigenomic, exosomal and other molecular technologies and includes products such as Confirm mdx, GPS mdx, ExoDx, Select mdx and Resolve mdx.
Recurring news for MDXH includes financial results, revenue guidance, tissue-based and liquid-based test volumes, clinical data for the Genomic Prostate Score test, and collaborations with academic prostate cancer researchers. Company updates also cover the integration of Exosome Diagnostics, earnout and warrant arrangements tied to diagnostic-test acquisitions, and corporate governance or management changes.
Mdxhealth (NASDAQ: MDXH) will release its second quarter 2026 financial results for the period ended June 30, 2026, after market close on Thursday, August 13, 2026. The company will host a results and corporate update conference call and webcast at 4:30pm ET / 22:30 CET, with live Q&A and a replay available on its website.
mdxhealth (NASDAQ: MDXH) received an additional Nasdaq notification on July 20, 2026 stating that the company no longer complies with the US$35 million minimum market value of listed securities required under Nasdaq Listing Rule 5550(b)(2), after its market value from June 1 to July 17, 2026 fell below this threshold.
The letter follows a prior notice about non-compliance with the $1.00 minimum bid price rule. Nasdaq has given mdxhealth 180 calendar days, until January 19, 2027, to regain compliance by maintaining market value above US$35 million for at least 10 consecutive business days. The notification does not currently affect the company’s Nasdaq Capital Market listing or business operations, and mdxhealth plans to monitor its market value and seek to cure the deficiency.
Mdxhealth (NASDAQ: MDXH) received a Nasdaq notice on June 30, 2026, stating its shares no longer meet the US$1.00 minimum bid price requirement for Nasdaq Capital Market listing.
The company has 180 days, until December 28, 2026, to regain compliance; operations remain unaffected, and options such as a reverse share split may be considered.
mdxhealth (NASDAQ: MDXH) announced peer-reviewed publication of the Oxford GPS-ProMPT study in European Urology Oncology, a leading genitourinary oncology journal.
The study is described as the first major milestone from the Oxford collaboration and the scientific foundation for the landmark GPS-ProtecT randomized controlled trial in localized prostate cancer.
According to investigators, patients with favorable GPS mdx scores showed 92% freedom-from-failure at six years in active surveillance and up to 100% in surgery and radiotherapy cohorts, even with adverse clinical risk factors. mdxhealth indicates these data may support GPS-related guideline development, payer coverage, and physician adoption.
mdxhealth (NASDAQ:MDXH) reported Q1 2026 revenue of $27.4 million, up 13% year over year, with pro-forma core revenue (excluding Resolve) of $23.9 million, up 11%.
The company will exit its Resolve mdx business and Plano lab, issued 2026 core cancer revenue guidance of $110–115 million (20–26% YoY growth), ended the quarter with $43.2 million cash, paid a $15 million ExoDx earnout in April, and is contesting a $10.4 million Medicare recoupment decision related to historical Resolve claims.
Mdxhealth (NASDAQ: MDXH) will release its first-quarter 2026 financial results for the period ended March 31, 2026, after market close on May 13, 2026. The company will host a conference call and live Q&A the same day at 4:30pm ET / 22:30 CET (Conference ID: MDX1Q26).
Investors may join via dial-in numbers for the US, Belgium, and UK or watch the webcast at the provided URL; the webcast replay will be available on the company website.
mdxhealth (NASDAQ: MDXH) presented late-breaking data from Oxford’s GPS-ProMPT study at EAU 2026 showing the Genomic Prostate Score (GPS mdx) predicts adverse outcomes across active surveillance, surgery, and radiotherapy.
The 409-patient cohort with a median follow-up of at least six years showed 6-year freedom-from-failure of 92% in active surveillance and up to 100% for surgery or radiotherapy, indicating GPS mdx can identify biologically indolent cancers among clinically higher-risk patients.
mdxhealth (NASDAQ: MDXH) reported fourth-quarter 2025 revenue of $29.5M (+19%) and full-year 2025 revenue of $107.9M (+20%). Gross profit rose to $69.6M for 2025 with gross margin at 64.5%. Adjusted EBITDA improved to ($1.1M) for 2025. Cash was $29.0M at year-end. The company reaffirmed 2026 revenue guidance of $137–140M and targets a 10% adjusted EBITDA margin exiting 2026.
MDxHealth (NASDAQ: MDXH) will release fourth quarter and full year 2025 financial results after market close on February 26, 2026. A conference call and live webcast with Q&A is scheduled for February 26, 2026 at 4:30pm ET / 22:30 CET.
Investors can join via listed dial‑in numbers or the provided webcast link and should connect 15 minutes early; a replay will be available on the company website.
MDxHealth (NASDAQ: MDXH) reported preliminary Q4 and full-year 2025 results and issued 2026 revenue guidance. The company expects Q4 2025 revenue of approximately $30.5M and full-year 2025 revenue of $109M, representing year-over-year growth of 23% and 21%, respectively. Volume highlights include 11,201 tissue-based and 27,486 liquid-based units billed in Q4; full-year volumes were 49,180 tissue and 71,920 liquid units. Year-end cash was $29.0M. 2026 revenue guidance is $137–140M (+26–28% YoY). The company amended earnout terms with Exact Sciences: remaining payments of $15.0M (2026), $18.0M (2027), and $21.5M (2028) and issued warrants for 3.0M common shares at a $5.265 exercise price.